Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Diabetic cardiomyopathy (DCM), although a distinct clinical entity, is also a part of the diabetic atherosclerosis process. It may be independent of the coexistence of ischemic heart disease, hypertension, or other macrovascular complications. Its pathological substrate is characterized by the presence of myocardial damage, reactive hypertrophy, and intermediary fibrosis, structural and functional changes of the small coronary vessels, disturbance of the management of the metabolic cardiovascular load, and cardiac autonomic neuropathy. These alterations make the diabetic heart susceptible to ischemia and less able to recover from an ischemic attack. Arterial hypertension frequently coexists with and exacerbates cardiac functioning, leading to the premature appearance of heart failure. Classical and newer echocardiographic methods are available for early diagnosis. Currently, there is no specific treatment for DCM; targeting its pathophysiological substrate by effective risk management protects the myocardium from further damage and has a recognized primary role in its prevention. Its pathophysiological substrate is also the objective for the new therapies and alternative remedies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“For each 1% reduction in HbA 1c , the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated a 14% reduction in myocardial infarction.(76) Moreover, impaired glucose tolerance has been identified as a risk factor for DCM, suggesting that even mild hyperglycemia may contribute to DCM.”
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883 · cited 1×
“This is valid for both type 1 and type 2 diabetes even when all other cardiovascular risk factors, such as hypertension, obesity, smoking, dyslipidemia, age, and sex, are taken into consideration.(6)”
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850 · cited 1×
“C-reactive protein is an acute-phase inflammation marker that has been associated with an increased risk for DCM.(90,91) Recent studies have confirmed the association between increased levels of C-reactive protein and worse LV myocardial performance, as well as risk factors for atherosclerosis and cardiovascular disea…”
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063 · cited 2×
“Hypertension per se is a major risk factor for vascular complications, ie, myocardial infarction and stroke.(103,104) According to major multicenter studies, the majority (almost 50%) of patients with diabetes and no clinical evidence of atheromatous disease are hypertensive or are taking antihypertensive drugs.”
Berenson, G. S., Srinivasan, S. R., Bao, W., Newman, W. P., Tracy, R. E., & Wattigney, W. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806043382302 · Cited by 4,032
Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults
Calle, E. E., Thun, M. J., Petrelli, J. M., Rodriguez, C., & Heath, C. W. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910073411501 · Cited by 3,643
Diabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833 · cited 1×
“In the Studies of Left Ventricular Dysfunction (SOLVD), the percentage of patients with diabetes and heart failure was up to 26%,(18) whereas in the Assessment Trial of Lisinopril and Survival (ATLAS) study, it was 19%(19) and in the Vasodilator-Heart Failure Trial II (V-HeFT II), it was up to 20%.(20) These findings…”
Advanced glycation end-products: A review
Singh, R., Barden, A., Mori, T., & Beilin, L. (2001) · Diabetologia · doi:10.1007/s001250051591 · Cited by 2,597 · cited 1×
“ROSs play an important role in the development of DCM.(42,43) Matrix metalloproteinase 2 (MMP-2) is activated by ROS and contributes to the acute loss of myocardial contractile function by targeting and cleaving susceptible proteins including troponin I and α-actinin.”
Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction
Vasan, R. S., Larson, S., Benjamin, E. J., Evans, J. C., Reiss, C. K., & Levy, D. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00118-7 · Cited by 1,331
Lipotoxic heart disease in obese rats: Implications for human obesity
Zhou, Y.-T., Grayburn, P., Karim, A., Shimabukuro, M., Higa, M., Baetens, D., Orci, L., & Unger, R. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1784 · Cited by 1,265
Norhammar, A., Tenerz, Å., Nilsson, G., Hamsten, A., Efendíc, S., Rydén, L., & Malmberg, K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09089-x · Cited by 1,112 · cited 1×
“Some studies have demonstrated that good glycemic control is associated with higher survival rates after acute myocardial infarction.(14) In diabetes subjects with angiographically proven coronary artery disease, the survival rates are decreased by 30% compared with their nondiabetes counterparts.”
Lamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G. R., Lupien, P. J., & Despre´s, J.-P. (1997) · Circulation · doi:10.1161/01.cir.95.1.69 · Cited by 1,077
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981 · cited 1×
“The STENO-2 Study demonstrated that in patients with type 2 diabetes, even when all associated cardiovascular risk factors are treated and the incidence of cardiovascular events is decreased by 50%, the cardiovascular mortality still remains high.(10) In one prospective study that included a population of 1,059 patien…”
Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H. J., & Lindner, J. (1996) · Diabetologia · doi:10.1007/s001250050617 · Cited by 873 · cited 1×
“150,151 The UKPDS evaluated the relationship between exposure to glycemia over time and the development of DCM in patients with type 2 diabetes.”
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome
Grundy, S. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00033-2 · Cited by 525 · cited 1×
“Dyslipidemia Increased atherogenesis and insulin resistance in diabetes and MetS have been attributed in large part to a proatherothrombotic dyslipidemia, related to hypertriglyceridemia, elevated very low-density lipoprotein, and decreased HDL cholesterol levels.(96,97) Insulin resistance results in increased levels…”
Shindler, D. M., Kostis, J. B., Yusuf, S., Quinones, M. A., Pitt, B., Stewart, D., Pinkett, T., Ghali, J. K., Wilson, A. C., & The SOLVD Investigators (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89163-1 · Cited by 516 · cited 1×
“In the Studies of Left Ventricular Dysfunction (SOLVD), the percentage of patients with diabetes and heart failure was up to 26%, 18 whereas in the Assessment Trial of Lisinopril and Survival (ATLAS) study, it was 19% 19 and in the Vasodilator-Heart Failure Trial II (V-HeFT II), it was up to 20%.”
Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options
Aneja, A., Tang, W. H. W., Bansilal, S., Garcia, M. J., & Farkouh, M. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.046 · Cited by 482 · cited 1×
“Continued research has provided novel insights into underlying molecular and pathophysiological mechanisms that increase the vulnerability of the diabetic heart to failure.(185) The choice of antidiabetic medication may influence the cardiovascular outcome.”
Palmieri, V., Bella, J. N., Arnett, D. K., Liu, J. E., Oberman, A., Schuck, M.-Y., Kitzman, D. W., Hopkins, P. N., Morgan, D., Rao, D. C., et al. (2001) · Circulation · doi:10.1161/01.cir.103.1.102 · Cited by 339 · cited 1×
“[128] 1,950 men + women with HTN (386 with DM) ↑ LV mass, ↑ LV relative wall thickness, concentric LV geometry, ↓ LV stress-corrected midwall shortening, ↓myocardial function (↓ midwall and ↓ stress-corrected midwall fractional shortening) 38% in both sexes”
Vascular dysfunction in diabetes mellitus
Feener, E. P., & King, G. L. (1997) · The Lancet · doi:10.1016/s0140-6736(97)90022-2 · Cited by 287 · cited 1×
“Although, the elevation and the imbalance of the cardiovascular and atherothrombotic metabolites and cytokines related to hyperinsulinemia and insulin resistance have a crucial contribution in the pathogenesis of DCM, it should be noted that the direct action of insulin on the vasculature has also been proposed to med…”
Overexpression of Metallothionein Reduces Diabetic Cardiomyopathy
Liang, Q., Carlson, E. C., Donthi, R. V., Kralik, P. M., Shen, X., & Epstein, P. N. (2002) · Diabetes · doi:10.2337/diabetes.51.1.174 · Cited by 182 · cited 1×
“Dyslipidemia and increased production of free oxygen radicals(48,49) may cause metabolic alterations to the genetic transcription factors and coding.(50,51) The result of these alterations is a modification in the translation of nucleoprotein genes, such as RAS and insulin-like growth factor 1 (IGF-1), responsible for…”
RYDEN, L. (2000) · European Heart Journal · doi:10.1053/euhj.2000.2311 · Cited by 174
Diabetes as a risk factor for sudden death
Balkau, B., Jouven, X., Ducimetière, P., & Eschwège, E. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04383-4 · Cited by 156 · cited 1×
“When the heart’s labor capacity is greatly reduced for a prolonged period, cardiac arrest and death are likely to happen.(67) Through predisposition to arrhythmias, CAN may lead to LV dysfunction followed by sudden death.”
Austin, M. A., & Edwards, K. L. (1996) · Current Opinion in Lipidology · doi:10.1097/00041433-199606000-00010 · Cited by 126
Kawaguchi, M., Techigawara, M., Ishihata, T., Asakura, T., Saito, F., Maehara, K., & Maruyama, Y. (1997) · Heart and Vessels · doi:10.1007/bf02766802 · Cited by 118 · cited 1×
“The Framingham Study demonstrated that the determination of LV hypertrophy electrocardiographically was not associated significantly with increased cardiovascular morbidity and mortality.(25) However, in the Framingham Study, when LV hypertrophy was assessed echocardiographically in a population of 3,222 patients, it…”
Cited by
Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy
Jia, G., DeMarco, V. G., & Sowers, J. R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.216 · Cited by 949
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
“In a diabetic heart, this metabolic flexibility is impaired and myocardium becomes more dependent on FFA oxidation as energy fuel [104,105].”
Self-citationWang, D., Luo, P., Wang, Y., Li, W., Wang, C., Sun, D., Zhang, R., Su, T., Ma, X., Zeng, C., et al. (2013) · Diabetes · doi:10.2337/db12-1025 · Cited by 179
Younce, C. W., Burmeister, M. A., & Ayala, J. E. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00248.2012 · Cited by 134
Voulgari, C., Katsilambros, N., & Tentolouris, N. (2011) · Metabolism · doi:10.1016/j.metabol.2011.02.014 · Cited by 90
Self-citation
Metadata
- Authors
- Voulgari, Tentolouris, N., & Papadogiannis, D.
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2010-10
- Volume
- 6
- Pages
- 883
- ISSN
- 1176-6344 (ISSN-L)
- 1178-2048
- OpenAlex
- W2020512380
- Cited by
- 210
- References
- 40
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.